Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28267000 | 0.93 | SMPD1 (0.52) | SMPD1EPHX2GBA1 | |
| SCHEMBL24569915 | 0.89 | P2RX7 (0.42) | SMPD1P2RX7GBA1 | |
| SCHEMBL19165673 | 0.81 | P2RX7 (0.37) | SMPD1P2RX7 | |
| SCHEMBL18707087 | 0.81 | — | — | |
| SCHEMBL3744192 | 0.78 | EP300 (0.47) | — | |
| SCHEMBL24345690 | 0.76 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL5490200 | 0.75 | SMPD1 (0.44) | SMPD1EPHX2GBA1 | |
| SCHEMBL23636794 | 0.75 | HDAC3 (0.46) | — | |
| SCHEMBL28260567 | 0.75 | HDAC3 (0.41) | SMPD1EPHX2 | |
| SCHEMBL11899559 | 0.74 | P2RX7 (0.42) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096211-B | Preparation method of polysubstituted triazole derivative | 华侨大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-109096211-A | A kind of preparation method of polysubstituted triazole derivatives | 华侨大学 | 2018-12-28 | — | — | CN | disclosed |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| WO-2012021390-A1 | LIGANDS AND METHODS FOR LABELING BIOMOLECULES IN VIVO | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | SMPD1 26/4885AMY1A 4766/4885P2RX7 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.